Avoro Ventures

Avoro Capital Advisors is a global life sciences investment firm based in New York, known for its strategic focus on biotechnology, life sciences, and specialty therapeutics. Founded as venBio Select Advisor, the firm has been instrumental in supporting emerging biotech companies that are driving innovation in the treatment of unmet medical needs. Avoro's investment strategy emphasizes identifying unique or undervalued opportunities in the market, often participating in both public and private investments across the biotech landscape. The firm’s portfolio includes a range of prominent companies such as Immunomedics (acquired by Gilead in 2020), MyoKardia (acquired by Bristol Myers Squibb), and Mirati Therapeutics, among others. Avoro is recognized for its hands-on approach, offering not just financial backing but also deep intellectual support to foster scientific breakthroughs. Avoro Ventures, a venture capital arm of the firm, extends this mission by focusing on early-stage investments in the drug discovery and healthcare tools sectors. The team is led by Managing Partner and Portfolio Manager Behzad Aghazadeh, who is highly regarded in the industry for his expertise in biopharmaceutical investments. With a comprehensive approach that includes rigorous risk management and a strong focus on innovation, Avoro Capital continues to be a key player in advancing biopharmaceutical developments.